Adjuvant therapy of colon cancer

Seminars in Oncology

Volumn 28, Issue 1, 2001, Pages 30-40

  Macdonald, John S ^a   Astrow, Alan B ^a  

^a Saint Vincents Comprehensive Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; COLON CARCINOMA; DOSE RESPONSE; HIGH RISK POPULATION; HUMAN; METASTASIS; PATIENT CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE; TREATMENT PLANNING;

EID: 0035114554     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90043-0     Document Type: Article

References (63)

1. Cancer statistics, 2000
2. Tumor DNA content in the prognosis of colorectal carcinoma
3. Consensus review of the clinical utility of DNA flow cytometry in colorectal cancer
4. Prognostic significance of flow cytometric analysis of DNA content in colorectal cancer. A prospective study
5. Current status of adjuvant chemotherapy for colorectal cancer
6. p53 nuclear over-expression: An independent predictor of survival in lymph node-positive colorectal cancer patients
7. Allelic loss of chromosome 18q and prognosis in colorectal cancer
8. Colorectal cancer
9. Colon cancer: A review of the epidemiology
10. Adjuvant therapy of colon cancer: Why we still don't know
11. Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil
12. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
13. The Inter-group study of 5-FU + levamisole and levamisole alone as adjuvant therapy for stage C colon cancer. A final report
14. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report
15. Inter-group study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer
16. Adjuvant 5FU plus levamisole improves survival in stage II and III colonic cancer, but not in rectal cancer. Interim analysis of the Netherlands Adjuvant Colorectal Cancer Project
17. Adjuvant therapy of colon cancer
18. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group Study
19. A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer
20. The Australia and New Zealand trial of adjuvant chemotherapy in colon cancer
21. Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control: Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I)
22. Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer
23. Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion
24. Adjuvant therapy of Dukes' A, B and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: Preliminary results of National Surgical Adjuvant Breast and Bowel Project protocol C-02
25. Long-term results of the efficacy of perioperative portal vein infusion of 5-FU for treatment of colon cancer: NSABP C-02
26. Randomized controlled trial of adjuvant chemotherapy by porta-vein perfusion after curative resection for colorectal adenocarcinoma
27. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma
28. Murine antiidiotype monoclonal antibody induces specific humoral responses to carcinoembryonic antigen (CEA) in colorectal cancer patients
29. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial
30. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
31. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: Preliminary results of INT-0089
32. The relative efficacy of 5-FU + leucovorin (FU-LV), 5-FU + levamisole (FU-LEV), and 5-FU + leucovorin + levamisole (FU-LV-LEV) in patients with Dukes' B and C carcinoma of the colon: First report of NSABP C-04
33. A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high-risk colon cancer: A collaborative trial of the North Central Cancer Treatment Group and The National Cancer Institute of Canada Clinical Trials Group
34. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer
35. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03
36. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
37. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer
38. The relative efficacy of 5-FU + leucovorin (FU-LV) and 5-FU-LV + interferon alfa-2a in patients with Dukes' B and C carcinoma of the colon: First report of NSABP C-05
39. New progress in immunotherapy for colorectal cancer patients
40. Fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer: Five-year final report of INT-0089
41. Comparative efficacy of adjuvant chemotherapy in patients with Dukes B vs. C colon cancer: Results from four NSABP adjuvant studies (CO1, CO2, CO3, CO4)
42. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer
43. Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin
44. Multicenter phase III study of 5-fluorouracil or UFT in combination with leucovorin in patients with metastatic colorectal cancer
45. Randomized comparative study of ORZEL plus leucovorin versus parenteral 5-fluorouracil plus leucovorin in patients with metastatic colorectal cancer
46. Phase I clinical and pharmacologic study of 776C85 plus 5-fluorouracil in patients with advanced cancer
47. Chemotherapy for gastric carcinoma: New and old options
48. The oral fluorouracil prodrugs
49. Tumor selectivity of Xeloda in colorectal cancer patients
50. A phase III trial of XELODA in previously untreated advanced metastatic colorectal cancer
51. Cisplatin and its analogues
52. A randomized trial of leucovorin and 5-fluorouracil with or without oxaliplatin in advanced colorectal cancer
53. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials
54. Weekly irinotecan, leucovorin, and fluorouracil is superior to daily × 5 LV/FU in patients with previously untreated metastatic colorectal cancer
55. Surgical therapy of hepatic colorectal metastasis
56. Surgical options in the treatment of hepatic metastasis from colorectal cancer
57. Hepatic resection for colorectal liver metastases: Influence on survival of preoperative factors and surgery for recurrences in 80 patients
58. Resection of hepatic metastases from colorectal cancer
59. Repeat hepatic resections for metastatic colorectal cancer
60. Surgery for recurrent colon cancer: Strategies for identifying resectable recurrence and success rates after resection
61. Results of the Intergroup (Eastern Cooperative Oncology Group (ECOG) and Southwest Oncology Group (SWOG)) prospective randomized study of surgery alone versus continuous hepatic artery infusion of FUDR and continuous systemic infusion of 5FU after hepatic resection for colorectal liver metastases